InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | 2026-05-08 | Cvijic Christine Mikail | Director & President and CFO | Sale | 4,800 | $30.07 | $144K | 98.4K | View ↗ | |
| 2026-03-26 | 2026-03-30 | Cvijic Christine Mikail | President and CFO | Sale | 2,558 | $21.62 | $55K | 103.2K | View ↗ | |
| 2026-03-26 | 2026-03-30 | McMinn Rachel | Director & Chief Executive Officer | Sale | 3,352 | $22.07 | $74K | 1.34M | View ↗ | |
| 2026-03-26 | 2026-03-30 | Jordan Julie | Chief Medical Officer | Sale | 828 | $21.89 | $18K | 12.5K | View ↗ | |
| 2026-03-13 | 2026-03-17 | Cvijic Christine Mikail | President and CFO | Sale | 4,045 | $20.81 | $84K | 105.8K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue under licensing agreements | $0-100.0% | $925K | $0 | — | — |
| Research and development expenses | $75.0M+23.1% | $60.9M+37.2% | $44.4M-6.5% | $47.5M | — |
| General and administrative expenses | $28.3M+25.2% | $22.6M+102.1% | $11.2M+24.2% | $9.0M-58.2% | $21.5M |
| Total operating expenses | $103.3M+23.7% | $83.5M+50.3% | $55.6M-1.7% | $56.5M | — |
| Loss from operations | -$103.3M-25.1% | -$82.6M-48.6% | -$55.6M+1.7% | -$56.5M-193.1% | $60.7M |
| Interest income | $11.5M+36.4% | $8.5M+186.9% | $3.0M+120.7% | $1.3M | — |
| Interest expense | -$5K+58.3% | -$12K+0.0% | -$12K-500.0% | -$2K | — |
| Other income | $1.7M+190.1% | $574K-96.5% | $16.4M | — | — |
| Other expense | -$230K+85.3% | -$1.6M-5500.0% | -$28K-300.0% | -$7K | — |
| Net loss | -$90.4M-20.2% | -$75.1M-106.9% | -$36.3M+34.2% | -$55.2M+9.1% | -$60.7M |
| Net loss per share, basic (in dollars per share) | -$4K+0.9% | -$4K | — | — | -$1K |
| Net loss per share, diluted (in dollars per share) | -$4K+0.9% | -$4K | — | — | -$1K |
| Weighted-average shares of common stock outstanding, basic (in shares) | $21.33B+21.4% | $17.57B | — | — | $55.04B |
| Weighted-average shares of common stock outstanding, diluted (in shares) | $21.33B+21.4% | $17.57B | — | — | $55.04B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth